The adaptor protein AMOT promotes the proliferation of mammary epithelial cells via the prolonged activation of the extracellular signal-regulated kinases

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2203-2211

  Ranahan, William P ^a   Han, Zhang ^a   Smith Kinnaman, Whitney ^a   Nabinger, Sarah C ^a   Heller, Brigitte ^a   Herbert, Britney Shea ^a   Chan, Rebecca ^a   Wells, Clark D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN AMOT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL AGGREGATION; CELL GROWTH; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LAMININ; LUMINESCENT PROTEINS; MAMMARY GLANDS, HUMAN; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PROTEOGLYCANS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR MICROENVIRONMENT;

EID: 79952769108     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1995     Document Type: Article

References (49)

1. Bissell MJ, Rizki A, Mian IS. Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol 2003;15:753-62. (Pubitemid 37487969)
2. Itoh M, Bissell MJ. The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia 2003;8:449-62. (Pubitemid 39137506)
3. Shin K, Fogg VC, Margolis B. Tight junctions and cell polarity. Annu Rev Cell Dev Biol 2006;22:207-35.
4. Nejsum LN, Nelson WJ. Epithelial cell surface polarity: the early steps. Front Biosci 2009;14:1088-98.
5. Rubin H. Cell-cell contact interactions conditionally determine suppression and selection of the neoplastic phenotype. Proc Natl Acad Sci U S A 2008;105:6215-21. (Pubitemid 351758326)
6. Feigin ME, Muthuswamy SK. Polarity proteins regulate mammalian cell-cell junctions and cancer pathogenesis. Curr Opin Cell Biol 2009;21:694-700.
7. Huang L, Muthuswamy SK. Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators. Curr Opin Genet Dev 20:41-50.
8. Nolan ME, Aranda V, Lee S, Lakshmi B, Basu S, Allred DC, et al. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res 2008;68:8201-9.
9. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, et al. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 2006;8:1235-45. (Pubitemid 44660588)
10. Wells CD, Fawcett JP, Traweger A, Yamanaka Y, Goudreault M, Elder K, et al. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 2006;125:535-48.
11. Heller B, Adu-Gyamfi E, Smith-Kinnaman W, Babbey C, Vora M, Xue Y, et al. Amot recognizes a juxtanuclear endocytic recycling compartment via a novel lipid binding domain. J Biol Chem 285:12308-20.
12. Ross JW, Ashworth MD, Stein DR, Couture OP, Tuggle CK, Geisert RD. Identification of differential gene expression during porcine conceptus rapid trophoblastic elongation and attachment to uterine luminal epithelium. Physiol Genomics 2009;36:140-8.
13. Aase K, Ernkvist M, Ebarasi L, Jakobsson L, Majumdar A, Yi C, et al. Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev 2007;21:2055-68. (Pubitemid 47267291)
14. Shimono A, Behringer RR. Angiomotin regulates visceral endoderm movements during mouse embryogenesis. Curr Biol 2003;13:613-7. (Pubitemid 36391942)
15. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE. Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 2006;6:16.
16. Colwill K, Wells CD, Elder K, Goudreault M, Hersi K, Kulkarni S, et al. Modification of the Creator recombination system for proteomics applications - improved expression by addition of splice sites. BMC Biotechnol 2006;6:13.
17. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256-68. (Pubitemid 36677560)
18. Levchenko T, Aase K, Troyanovsky B, Bratt A, Holmgren L. Loss of responsiveness to chemotactic factors by deletion of the C-terminal protein interaction site of angiomotin. J Cell Sci 2003;116 (Pt 18): 3803-10. (Pubitemid 37185309)
19. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001;56:127-55.
20. Ahn NG. The MAP kinase cascade. Discovery of a new signal transduction pathway. Mol Cell Biochem 1993;127-128:201-9.
21. Cobb MH, Goldsmith EJ. How MAP Kinases Are Regulated. J Biol Chem 1995;270:14843-14846.
22. Brown MD, Sacks DB. Protein scaffolds in MAP kinase signalling. Cell Signal 2009;21:462-9.
23. Burack WR, Shaw AS. Live cell imaging of ERK and MEK: simple binding equilibrium explains the regulated nucleocytoplasmic distribution of ERK. J Biol Chem 2005;280:3832-7. (Pubitemid 40223853)
24. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995;14:951-62.
25. Shaw PE, Saxton J. Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Int J Biochem Cell Biol 2003; 35:1210-26. (Pubitemid 36577311)
26. Murphy LO, Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006;31:268-75. (Pubitemid 43674354)
27. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouysségur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-74. (Pubitemid 29057251)
28. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 2008;5:280-90.
29. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004;83:249-89. (Pubitemid 38264873)
30. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69:565-72.
31. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 2005;12 Suppl 1:S1-7.
32. LaBarge MA, Petersen OW, Bissell MJ. Of microenvironments and mammary stem cells. Stem Cell Rev 2007;3:137-46. (Pubitemid 350129716)
33. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41. (Pubitemid 46160912)
34. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2- targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010;122:35-43.
35. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16. (Pubitemid 44036456)
36. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009;28:461-8.
37. Lu H, Bilder D. Endocytic control of epithelial polarity and proliferation in Drosophila. Nat Cell Biol 2005;7:1232-9.
38. Muralidharan-Chari V, Hoover H, Clancy J, Schweitzer J, Suckow MA, Schroeder V, et al. ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo. Cancer Res 2009;69:2201-9.
39. Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M, et al. Differences on the inhibitory specificities of H-Ras, KRas, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem 2003;278:4572-81.
40. Casar B, Arozarena I, Sanz-Moreno V, Pinto A, Agudo-Ibáñez L, Marais R, et al. Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol Cell Biol 2009;29:1338-53.
41. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 2002;4:343-50. (Pubitemid 34521029)
42. Willard MD, Willard FS, Li X, Cappell SD, Snider WD, Siderovski DP. Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation. EMBO J 2007;26:2029-40. (Pubitemid 46625794)
43. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 2009;11:1444-50.
44. Grusche FA, Richardson HE, Harvey KF. Upstream regulation of the hippo size control pathway. Curr Biol 2010;20:R574-82.
45. Bakal C, Linding R, Llense F, Heffern E, Martin-Blanco E, Pawson T, et al. Phosphorylation networks regulating JNK activity in diverse genetic backgrounds. Science 2008;322:453-6.
46. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, LaenkholmAV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009;114:263-75.
47. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000;19:6102-14. (Pubitemid 32059460)
48. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005;92:2206-15. (Pubitemid 40966259)
49. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002;8:1747-53. (Pubitemid 34633730)